Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Benitec Biopharma Inc. logo

NASDAQ · BNTC

Benitec Biopharma Inc.

Healthcare · Biotechnology

$8.74

Down-$0.09 (-1.02%)

Updated Nov 1, 2026, 8:26 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
339.64M
P/E ratio
-12.85
Dividend yield
0.00%
52-week range
$7.89 – $14.33
Volume
135.49K
Avg. volume
175.77K

Price performance · BNTC

BNTC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

BNTC closed at $8.74 after 20 trading sessions, down 5.31% for the selected period.

Last close
$8.74
Period change
-5.31%
Period low
$8.11
Period high
$9.23
Daily close
View OHLC price history
BNTC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$8.80$8.93$8.4289$8.74135.49K
Oct 29, 2026$8.73$9.11$8.73$8.83162.54K
Oct 28, 2026$7.885$8.91$7.885$8.80238.6K
Oct 27, 2026$8.60$8.8492$8.52$8.68156.89K
Oct 26, 2026$8.71$8.80$8.54$8.5998.63K
Oct 23, 2026$8.91$8.91$8.53$8.65158.39K
Oct 22, 2026$8.47$8.85$8.21$8.82149.01K
Oct 21, 2026$9.05$9.2199$8.40$8.50171.85K
Oct 20, 2026$8.35$9.29$8.32$9.04347.6K
Oct 19, 2026$8.13$8.618$8.00$8.36194.12K
Oct 16, 2026$8.47$8.47$8.06$8.11158.56K
Oct 15, 2026$8.37$8.758$8.34$8.46153.73K
Oct 14, 2026$8.52$9.07$8.25$8.29162.5K
Oct 13, 2026$9.08$9.08$8.51$8.63151.4K
Oct 12, 2026$8.90$9.25$8.75$9.07200.9K
Oct 9, 2026$8.72$9.03$8.71$8.8773.14K
Oct 8, 2026$8.86$8.97$8.61$8.75234.86K
Oct 7, 2026$8.81$9.27$8.80$8.99190.06K
Oct 6, 2026$9.32$9.565$8.62$9.00217.15K
Oct 5, 2026$9.00$9.99$8.52$9.23584.24K

Latest BNTC news

The latest Smart Investors Daily articles mentioning BNTC.

Stock researchCompany · Overview

BNTC research

Overview

Company profile and research snapshot.

Company profile

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$27.67
Implied upside
—
Analysts
—
BNTC recent ratings
DateFirmRatingTarget
Oct 23, 2026Raymond JamesOutperform—
Sep 15, 2026WedbushOutperform—
Jul 28, 2026WedbushOutperform—
May 12, 2026Evercore ISI GroupOutperform—
Mar 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

- Both low dose and high dose BB-301 continue to drive robust improvements in swallowing function for dysphagic Patients with Oculopharyngeal Muscular Dystrophy (OPMD) - 100% of Patients treated with BB-301 across both doses are formal Responders to therapy - Interim clinical results for Patients treated with high dose BB-301 demonstrate greater relative improvements at the 3-month post-treatment time-point in throat emptying ability (assessed by videofluoroscopic evaluation of post-swallow food

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By